News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Insider Monkey190d agoneutral
ANKTIVA Strong Demand Propels ImmunityBio, Inc. (IBRX) to Robust Revenue GrowthSimply Wall St.198d agoneutral
Does Saudi ANKTIVA Launch Signal a New Phase in ImmunityBio’s (IBRX) Commercial Strategy?Insider Monkey198d agoneutral
ImmunityBio, Inc. (IBRX) Expands ANKTIVA Access With First Commercial Use in Saudi ArabiaInsider Monkey201d agoneutral
Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look”